Form 8-K - Current report:
SEC Accession No. 0000875320-25-000171
Filing Date
2025-05-05
Accepted
2025-05-05 16:10:03
Documents
14
Period of Report
2025-05-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K vrtx-20250505.htm   iXBRL 8-K 25140
2 EX-99.1 ex-991_q12025.htm EX-99.1 200749
  Complete submission text file 0000875320-25-000171.txt   375392

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT vrtx-20250505.xsd EX-101.SCH 1870
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT vrtx-20250505_lab.xml EX-101.LAB 21885
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT vrtx-20250505_pre.xml EX-101.PRE 12595
17 EXTRACTED XBRL INSTANCE DOCUMENT vrtx-20250505_htm.xml XML 2720
Mailing Address 50 NORTHERN AVENUE BOSTON MA 02210
Business Address 50 NORTHERN AVENUE BOSTON MA 02210 6173416393
VERTEX PHARMACEUTICALS INC / MA (Filer) CIK: 0000875320 (see all company filings)

EIN.: 043039129 | State of Incorp.: MA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-19319 | Film No.: 25913013
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)